Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (212)	12/30/1997 10:00:00 PM
From: diablo	Read Replies (1) \| Respond to of 1494

any further word on the status of the trials?

To: Dr. John M. de Castro who wrote (212)	1/15/1998 11:55:00 AM
From: JMarcus	Respond to of 1494

From the Neurex thread, NeuroInvestment writes: 2) If you want something genuine to worry about, look for the release of the neuropathic pain Phase II data from the Neurobiological Technologies memantine trial, due out late Jan/early Feb. While I expect memantine to have less magnitude of effect, it is given orally and thus is a lot cheaper and easier to utilize. If successful, NTI would push a Phase III partnership ASAP, since they are near bankrupt.It could be a competitor for the mild-moderate range of neuropathic pain patients. NeuroInvestment Message 3174189 Today, Jan. 15, is the big day for NTIIC. Sadly, you weren't right about a news release prior to this date. The stock is down on low volume. I'd have expected more volume today, one way or the other.